ATE322496T1 - 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten - Google Patents

4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten

Info

Publication number
ATE322496T1
ATE322496T1 AT01960529T AT01960529T ATE322496T1 AT E322496 T1 ATE322496 T1 AT E322496T1 AT 01960529 T AT01960529 T AT 01960529T AT 01960529 T AT01960529 T AT 01960529T AT E322496 T1 ATE322496 T1 AT E322496T1
Authority
AT
Austria
Prior art keywords
neurokinin
receptor antagonists
phenylpyridine derivatives
phenylpyridine
derivatives
Prior art date
Application number
AT01960529T
Other languages
German (de)
English (en)
Inventor
Torsten Hoffmann
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE322496T1 publication Critical patent/ATE322496T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01960529T 2000-07-24 2001-07-20 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten ATE322496T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24

Publications (1)

Publication Number Publication Date
ATE322496T1 true ATE322496T1 (de) 2006-04-15

Family

ID=8169331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01960529T ATE322496T1 (de) 2000-07-24 2001-07-20 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten

Country Status (37)

Country Link
US (2) US6576762B2 (enExample)
EP (1) EP1305319B1 (enExample)
JP (1) JP4118673B2 (enExample)
KR (1) KR100527214B1 (enExample)
CN (1) CN1192032C (enExample)
AR (1) AR029875A1 (enExample)
AT (1) ATE322496T1 (enExample)
AU (2) AU2001282005B2 (enExample)
BR (1) BR0112695A (enExample)
CA (1) CA2416874C (enExample)
CY (1) CY1106113T1 (enExample)
CZ (1) CZ2003528A3 (enExample)
DE (1) DE60118569T2 (enExample)
DK (1) DK1305319T3 (enExample)
EC (1) ECSP034446A (enExample)
ES (1) ES2260265T3 (enExample)
GT (1) GT200100148A (enExample)
HR (1) HRP20030031A2 (enExample)
HU (1) HU229231B1 (enExample)
IL (2) IL153837A0 (enExample)
JO (1) JO2321B1 (enExample)
MA (1) MA26933A1 (enExample)
MX (1) MXPA03000367A (enExample)
MY (1) MY129224A (enExample)
NO (1) NO20030353L (enExample)
NZ (1) NZ523452A (enExample)
PA (1) PA8522801A1 (enExample)
PE (1) PE20020258A1 (enExample)
PL (1) PL366173A1 (enExample)
PT (1) PT1305319E (enExample)
RU (1) RU2276139C2 (enExample)
SI (1) SI1305319T1 (enExample)
TW (1) TWI287003B (enExample)
UY (1) UY26851A1 (enExample)
WO (1) WO2002008232A1 (enExample)
YU (1) YU2803A (enExample)
ZA (1) ZA200300219B (enExample)

Families Citing this family (23)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
ES2307925T3 (es) 2002-04-26 2008-12-01 Eli Lilly And Company Antagonistas de los receptores de la taquiquinina.
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
WO2004032875A2 (en) * 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
RU2347777C2 (ru) * 2003-07-03 2009-02-27 ะค.ะฅะพั„ั„ะผะฐะฝะฝ-ะ›ั ะ ะพัˆ ะะณ ะ”ะฒะพะนะฝั‹ะต ะฐะณะพะฝะธัั‚ั‹ nk1/nk3 ะดะปั ะปะตั‡ะตะฝะธั ัˆะธะทะพั„ั€ะตะฝะธะธ
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 ๅผ—ยทๅ“ˆๅคซๆ›ผ-ๆ‹‰็ฝ—ๅˆ‡ๆœ‰้™ๅ…ฌๅธ ็”จไฝœๅˆๆˆnk-1ๅ—ไฝ“ๆ‹ฎๆŠ—ๅ‰‚็š„ไธญ้—ดไฝ“็š„็”ฒ้…ฐ่ƒบๅกๅ•ถ่ก็”Ÿ็‰ฉ็š„ๅˆถๅค‡ๆ–นๆณ•
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ใƒŸใ‚ทใƒฃใƒญใ‚ฆใ€ใ‚ขใƒฌใ‚ฏใ‚ตใƒณใƒ€ใƒผ ๅฏพๆŠ—้ฉๅฟœใ‚’่ช˜็™บใ™ใ‚‹ใ“ใจใซใ‚ˆใ‚Š็ฅž็ตŒไผ้”็‰ฉ่ณช็ณปใ‚’่ชฟ็ฏ€ใ™ใ‚‹ๆ–นๆณ•
KR20070094666A (ko) 2005-02-25 2007-09-20 ์—ํ”„. ํ˜ธํ”„๋งŒ-๋ผ ๋กœ์Šˆ ์•„๊ฒŒ ์•ฝ์ œ ๋ฌผ์งˆ ๋ถ„์‚ฐ์„ฑ์ด ํ–ฅ์ƒ๋œ ์ •์ œ
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
MX2008014796A (es) 2006-05-31 2008-12-02 Hoffmann La Roche Derivados de aril-4-etinil-isoxazol.
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
TWI649307B (zh) 2014-05-07 2019-02-01 ๆ—ฅๅ•†ๆฉ˜็”Ÿ่—ฅๅ“ๅทฅๆฅญ่‚กไปฝๆœ‰้™ๅ…ฌๅธ Cyclohexylpyridine derivative
US10538491B2 (en) 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
CN115531553A (zh) 2015-12-22 2022-12-30 ๆญฆ็”ฐ่ฏๅ“ๅทฅไธšๆ ชๅผไผš็คพ ๅ†…ไฝ“g่›‹็™ฝ-ๅถ่”็š„ๅ—ไฝ“็š„ไธ‰้ƒจๅˆ†่ฐƒ่Š‚ๅ‰‚
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain

Family Cites Families (13)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd ่ค‡็ด ็’ฐๅŒ–ๅˆ็‰ฉใ€ใใฎ่ฃฝ้€ ๆณ•ใŠใ‚ˆใณ็”จ้€”
KR20010041991A (ko) 1998-03-19 2001-05-25 ๋‹ค์ผ€๋‹ค ์•ผ์ฟ ํžŒ ๊ณ ๊ต ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ๋ณต์†Œํ™˜์‹ ํ™”ํ•ฉ๋ฌผ, ๊ทธ์˜ ์ œ์กฐ๋ฒ• ๋ฐ ํƒ€ํ‚คํ‚ค๋‹Œ ์ˆ˜์šฉ์ฒด๊ธธํ•ญ์•ฝ์œผ๋กœ์„œ์˜ ์šฉ๋„
TR200102490T2 (tr) * 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil tรผrevleri
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
KR100437587B1 (ko) * 1999-02-24 2004-06-30 ์—ํ”„. ํ˜ธํ”„๋งŒ-๋ผ ๋กœ์Šˆ ์•„๊ฒŒ 3-ํŽ˜๋‹ํ”ผ๋ฆฌ๋”˜ ์œ ๋„์ฒด ๋ฐ ๊ทธ์˜ ๋‰ด๋กœํ‚ค๋‹Œ-1 ์ˆ˜์šฉ์ฒด๊ธธํ•ญ์ œ๋กœ์„œ์˜ ์šฉ๋„
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
MXPA03000366A (es) * 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.

Also Published As

Publication number Publication date
PT1305319E (pt) 2006-08-31
US6624176B2 (en) 2003-09-23
DK1305319T3 (da) 2006-08-14
CZ2003528A3 (cs) 2003-09-17
NO20030353D0 (no) 2003-01-23
CA2416874A1 (en) 2002-01-31
CN1444589A (zh) 2003-09-24
PA8522801A1 (es) 2002-09-30
EP1305319A1 (en) 2003-05-02
CA2416874C (en) 2011-01-18
ZA200300219B (en) 2004-04-08
GT200100148A (es) 2002-05-16
HK1058360A1 (en) 2004-05-14
IL153837A0 (en) 2003-07-31
AU2001282005B2 (en) 2006-10-19
ECSP034446A (es) 2003-03-10
IL153837A (en) 2008-06-05
JP4118673B2 (ja) 2008-07-16
US6576762B2 (en) 2003-06-10
YU2803A (sh) 2006-01-16
KR100527214B1 (ko) 2005-11-08
KR20030015898A (ko) 2003-02-25
HRP20030031A2 (en) 2004-02-29
WO2002008232A1 (en) 2002-01-31
ES2260265T3 (es) 2006-11-01
MY129224A (en) 2007-03-30
AU8200501A (en) 2002-02-05
MXPA03000367A (es) 2003-05-27
JO2321B1 (en) 2005-09-12
EP1305319B1 (en) 2006-04-05
HU229231B1 (en) 2013-09-30
JP2004504400A (ja) 2004-02-12
TWI287003B (en) 2007-09-21
NO20030353L (no) 2003-01-23
CN1192032C (zh) 2005-03-09
US20020038030A1 (en) 2002-03-28
DE60118569D1 (de) 2006-05-18
MA26933A1 (fr) 2004-12-20
NZ523452A (en) 2004-07-30
CY1106113T1 (el) 2011-06-08
DE60118569T2 (de) 2007-02-15
HUP0301272A2 (hu) 2003-08-28
SI1305319T1 (sl) 2006-08-31
PE20020258A1 (es) 2002-04-02
US20030130508A1 (en) 2003-07-10
UY26851A1 (es) 2002-01-31
BR0112695A (pt) 2003-04-22
PL366173A1 (en) 2005-01-24
AR029875A1 (es) 2003-07-16
RU2276139C2 (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE322496T1 (de) 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten
ATE368659T1 (de) Thrombinrezeptorantagonisten
ATE381565T1 (de) 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten
DE60318697D1 (de) Triazolderivate als tachykininrezeptor-antagonisten
ATE400558T1 (de) Metabotropische glutamatrezeptor-antagonisten
NO20025754D0 (no) IL-8 Reseptor-antagonister
ATE299698T1 (de) Il-8 rezeptor antagonisten
DE60126480D1 (de) Il-8 rezeptor-antagonisten
ATE286018T1 (de) Biphenylderivate als neurokinin-1 antagonisten
DE50100358D1 (de) Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
MA25739A1 (fr) Antagonistes recepteurs il-8
NO20024367D0 (no) IL-8 reseptorantagonister
NO20024366L (no) IL-8 reseptorantagonister
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1305319

Country of ref document: EP